Analysts at Bernstein initiated coverage on Regeneron Pharmaceuticals, Inc. REGN with a Outperform rating.
The target price for Regeneron Pharmaceuticals is set to $475.
Regeneron Pharmaceuticals shares have gained 20.92% over the past 52 weeks, while the S&P 500 index has surged 13.92% in the same period.
Regeneron Pharmaceuticals' shares rose 0.16% to close at $402.40 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in